Cytochrome P450 (CYP) proteins are responsible for breaking down more than 80% of all Food and Drug Administration (FDA)-approved drugs, reducing their effectiveness. However, how to prevent CYPs from doing this without off-target effects has puzzled researchers until now.
Scientists at St. Jude Children’s Research Hospital have designed new drug frameworks that selectively target CYP3A4, one of the most critical CYP proteins. Structural insights from this work offer a roadmap for future drug developers to better evaluate drug interactions and selectively target CYP proteins. The findings are published in Nature Communications.
CYP3A4 breaks down drugs that treat various health conditions, including the anti-cancer agent paclitaxel and the COVID-19 therapeutic nirmatrelvir. CYP3A4 inhibitors are commonly co-administered to reduce CYP3A4’s effect. This includes ritonavir, which is combined with nirmatrelvir in Paxlovid for mild COVID-19 treatment. However, such CYP3A4 inhibitors often affect the similar but distinct CYP3A5 due to the two proteins’ shared features, such as large and promiscuous binding sites, in addition to other unintended CYPs.